Virpax Pharmaceuticals, Inc. Common Stock
VRPX
VRPX was delisted on the 3rd of April, 2025.
4 hedge funds and large institutions have $1.29M invested in Virpax Pharmaceuticals, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
5.56% more ownership
Funds ownership: 0% → 5.56% (+5.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.07M |
| 2 |
ZCA
Zeke Capital Advisors
Berwyn,
Pennsylvania
|
+$242K |
| 3 |
SC
Saltoro Capital
Dallas,
Texas
|
+$145K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$16.1K |
Top Sellers
VRPX Hedge Fund Activity: Q1 2021 in Review
4 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Virpax Pharmaceuticals, Inc. Common Stock (VRPX) for Q1 2021, worth a combined $1.29M.
Buyers outnumbered sellers: 4 funds opened new VRPX positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.07M.
- 4 institutional investors held Virpax Pharmaceuticals, Inc. Common Stock (VRPX) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $1.29M of Virpax Pharmaceuticals, Inc. Common Stock stock for Q1 2021.
- 4 funds opened new Virpax Pharmaceuticals, Inc. Common Stock positions in Q1 2021 and 0 closed out, a net change of +4 holders.
- The largest Virpax Pharmaceuticals, Inc. Common Stock buyer in Q1 2021 was Sabby Management, an estimated $1.07M added.
Based on aggregated 13F filings for Q1 2021.